BIOMARKER AND PATIENT SELECTION IN TREATMENT FOR MYELOFIBROSIS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 10, 2025
app pub date -
Jul 29, 2022
filing date -
Jul 29, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Transfusion independence in, and overall survival of, myelofibrosis patients can be improved by selecting a patient specific treatment method. A patient's baseline ferritin level can be used as a biomarker to select a first line treatment. The patient's ferritin levels during treatment can inform decisions about terminating treatment or changing treatments to maintain transfusion dependence and/or convert a patient to transfusion independent from transfusion requiring or transfusion dependent.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully